Evaluation of Swallowing Muscles Using Ultrasonography and Shear Wave Elastography in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma Diagnosis
NCT ID: NCT06934837
Last Updated: 2025-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2023-01-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiation-Related Dysphagia Development Prediction Using a Two-Step Ultrasonographic Model (R-2D-2)
NCT06387004
Pre-treatment Exercises Versus Post-treatment Exercises for Dysphagia
NCT00584129
Electromyographic Activity of Masseter Muscle During Deglutition in Total Laryngectomized Subjects
NCT01095289
Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy
NCT01237704
Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC)
NCT00815087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients were interviewed to obtain detailed medical histories. Following this, standardized swallowing assessments were administered, including the Eating Assessment Tool (EAT-10) and the M.D. Anderson Dysphagia Inventory (MDADI). Head and neck examination, endoscopic examination and fibreoptic endoscopic swallowing assessment were performed at the Otorhinolaryngology, Head and Neck Surgery clinic. Penetration Aspiration Score (PAS) was determined by the experienced faculty member. Afterwards, an experienced radiologist performed neck ultrasonography and shear wave elastography (SWE) using an Aplio 500 Platinium Ultrasonography system (Toshiba Medical Systems, Japan) equipped with high-frequency linear transducer (frequency range = 5-14 MHz). With SWE, the stiffness values of the mylohyoid, geniohyoid and digastric muscles were measured in m/s and kPa, and their thickness was measured in mm. The tissue elasticity was outlined using a colour-coded system ranging from dark blue indicating least stiffness to red representing greatest stiffness, with a default measurement range of 0-120 kPa. The elastic value E (kPa) is calculated using the equation E = 3 ρ (m/s) 2. In the equation, m/s represents the shear wave propagation speed, and ρ represents the tissue density (approximately 1 in humans). All patients receiving radiotherapy were treated in our hospital's radiation oncology clinic for Stage I nasopharyngeal cancer received 70 Gy (2,12 Gy/Gun) gross tumour value (CTV70), with 5-10 mm margin for microscopic spread, delivered according to the International Commission on Radiation Units and Measurements (ICRU) Reports 50 and 62 guidelines. After obtaining the data, comparisons between the groups and correlations between the quantitative data were assessed using appropriate statistical methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nasopharynx canser (disease group)
16 Stage I nasopharynx cancer patients receiving radiotherapy
No interventions assigned to this group
Control (healthy) group
16 healthy volunteers from the otorhinolaryngology outpatient clinic
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteered for the study.
* Aged 18-65 years.
* Diagnosed with Stage I nasopharynx cancer.
* Completed radiotherapy treatment at least 12 months prior to the study.
* No additional cancer diagnoses.
* No history of chemo-radiotherapy.
* No prior head-neck trauma or surgery.
* No rheumatologic or neuromuscular disorders.
* No pre-existing swallowing disorders.
* Control Group (Healthy Volunteers):
Control group:
* Aged 18-65 years.
* No history of head and neck cancer.
* No prior neck surgery or trauma.
* No radiotherapy to the head and neck region.
* No rheumatologic or neuromuscular disorders.
* No central haemorrhagic or ischemic disease.
* No pre-existing swallowing disorders.
Exclusion Criteria
* Any history of neck interventions (e.g., for cancer metastasis, cervical spine surgery, trauma).
* Presence of systemic conditions potentially causing dysphagia (e.g., neurological, rheumatological, metabolic, or muscular disorders).
* Previous radiotherapy for reasons other than Stage I nasopharynx cancer (in the patient group).
* Any other cancer diagnosis besides Stage I nasopharynx cancer (in the patient group).
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Selcuk University
OTHER
Konya Beyhekim Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatih İkiz
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Selçuk University Faculty of Medicine Hospital
Konya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUFM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.